Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study

Details

Request a copyRequest a copy
Serval ID
serval:BIB_9730537ABE4F
Type
Inproceedings: an article in a conference proceedings.
Publication sub-type
Abstract (Abstract): shot summary in a article that contain essentials elements presented during a scientific conference, lecture or from a poster.
Collection
Publications
Institution
Production externe
Title
Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study
Title of the conference
Blood
Author(s)
Yong Kwee, Hinsley Samantha, Sherratt Debbie, Kendall Jessica, Brown Sarah R, Flanagan Louise, Williams Catherine, Cavenagh Jamie, Kaiser Martin, Rabin Neil K, Ramasamy Karthik, Garg Mamta, Auner Holger W., Hawkins Stephen F., Bygrave Ceri, De Tute Ruth M, Morgan Gareth, Davies Faith E., Owen Roger G.
Publisher
American Society of Hematology
Organization
60th Annual Meeting of the American-Society-of-Hematology (ASH)
Address
San Diego, CA
ISSN
0006-4971
1528-0020
Publication state
Published
Issued date
29/11/2018
Volume
132
Number
Supplement 1
Pages
306-306
Language
english
DOI
10.1182/blood-2018-99-116624
Web of science
000454837601015
Open Access
Yes
Create date
02/12/2024 17:49
Last modification date
04/12/2024 8:07
Usage data